These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35144846)

  • 41. Subclinical myopathic changes in COVID-19.
    Villa D; Ardolino G; Borellini L; Cogiamanian F; Vergari M; Savojardo V; Peyvandi F; Barbieri S
    Neurol Sci; 2021 Oct; 42(10):3973-3979. PubMed ID: 34304328
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Investigating mortality trends in Italy during the COVID-19 pandemic: life expectancy changes within provinces and vaccination campaign impact up to December 2022.
    Nova A; Fazia T; Bernardinelli L
    Public Health; 2023 Dec; 225():168-175. PubMed ID: 37925841
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early evidence of SARS-CoV-2 in Milan, Jan-Feb 2020.
    Milani GP; Casazza G; Corsello A; Marchisio P; Rocchi A; Colombo G; Agostoni C; Costantino G
    Ital J Pediatr; 2021 Jun; 47(1):145. PubMed ID: 34193222
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [New role for hospital department directors in a Milan hospital, Italy].
    Pavan A; Longo M; Giusepi I; Macchi L
    Ig Sanita Pubbl; 2013; 69(5):497-504. PubMed ID: 24316877
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Attitudes of Healthcare Personnel towards Vaccinations before and during the COVID-19 Pandemic.
    Ledda C; Costantino C; Cuccia M; Maltezou HC; Rapisarda V
    Int J Environ Res Public Health; 2021 Mar; 18(5):. PubMed ID: 33800187
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dermoscopy Use Leads to Earlier Cutaneous Melanoma Diagnosis in Terms of Invasiveness and Size? A Single-Center, Retrospective Experience.
    Nazzaro G; Passoni E; Pozzessere F; Maronese CA; Marzano AV
    J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36013151
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Technical guidelines for seasonal influenza vaccination in China (2021-2022)].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) , Influenza Vaccination TWG
    Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Oct; 42(10):1722-1749. PubMed ID: 34814607
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Can we get out of the COVID pandemic without adequate vaccination coverage in the pediatric population?
    Esposito S; Giordano R; Paini G; Puntoni M; Principi N; Caminiti C
    Ital J Pediatr; 2022 Aug; 48(1):150. PubMed ID: 35986340
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The clinical and pathologic spectrum of mucocutaneous reactions after COVID-19 vaccinations in three tertiary referral centers of northern Italy.
    Paolino G; Caputo V; Schroeder J; Marzano AV; Bonoldi E; Moltrasio C; Maronese CA; Borgonovo L; Rongioletti F
    Clin Dermatol; 2023; 41(2):312-319. PubMed ID: 36863621
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Implementation of the COVID-19 vaccination campaign: experiences and perspectives from the point of view of the Association of Statutory Health Insurance Physicians Westfalen-Lippe (KVWL)].
    Meyer F; Schwenzer C; Spelmeyer D
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2022 Dec; 65(12):1262-1271. PubMed ID: 36434393
    [TBL] [Abstract][Full Text] [Related]  

  • 51. How many lives do COVID vaccines save? Evidence from Israel.
    Arbel R; Moore CM; Sergienko R; Pliskin J
    Am J Infect Control; 2022 Mar; 50(3):258-261. PubMed ID: 34971714
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Initial impact of SARS-Cov-2 vaccination on healthcare workers in Italy- Update on the 28th of March 2021.
    Mateo-Urdiales A; Del Manso M; Andrianou X; Spuri M; D'Ancona F; Filia A; Rota MC; Petrone D; Vescio MF; Riccardo F; Bella A; Pezzotti P; Fabiani M
    Vaccine; 2021 Aug; 39(34):4788-4792. PubMed ID: 34253419
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influenza and pneumococcal vaccinations are not associated to COVID-19 outcomes among patients admitted to a university hospital.
    Pastorino R; Villani L; La Milia DI; Ieraci R; Chini F; Volpe E; Barca A; Fusco D; Laurenti P; Ricciardi W; Boccia S
    Vaccine; 2021 Jun; 39(26):3493-3497. PubMed ID: 34020813
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Potential for elimination of SAR-CoV-2 through vaccination as inspired by elimination of multiple influenza viruses through natural pandemics or mass vaccination.
    Chen JM; Sun YX; Chen JW
    J Med Virol; 2020 Nov; 92(11):2453-2457. PubMed ID: 32525587
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reactive mass vaccination campaign against cholera in the COVID-19 context in Cameroon: challenges, best practices and lessons learned.
    Amani A; Fouda AAB; Nangmo AJ; Bama SN; Tatang CA; Mbang MA; Douba ECE; Noula AGM; Dia M; Bouhenia M
    Pan Afr Med J; 2021; 38():392. PubMed ID: 34381536
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Considerations for Establishing Successful Coronavirus Disease Vaccination Programs in Africa.
    Williams V; Edem B; Calnan M; Otwombe K; Okeahalam C
    Emerg Infect Dis; 2021 Aug; 27(8):2009-2016. PubMed ID: 34138694
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Validation Checklist for Massive Vaccination Centers.
    Capolongo S; Brambilla A; Girardi A; Signorelli C
    Ann Ig; 2021; 33(5):513-517. PubMed ID: 34224553
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improving Risk Management by Learning from Adverse Events: Report on One Year of COVID-19 Vaccination Campaign in Verona (Northeastern Italy).
    Tocco Tussardi I; Tardivo S
    Int J Environ Res Public Health; 2022 Mar; 19(6):. PubMed ID: 35329322
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Offering onsite COVID-19 vaccination to high-risk obstetrical patients: initial findings.
    Hirshberg JS; Huysman BC; Oakes MC; Cater EB; Odibo AO; Raghuraman N; Kelly JC
    Am J Obstet Gynecol MFM; 2021 Nov; 3(6):100478. PubMed ID: 34481996
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network.
    Neuhann JM; Stemler J; Carcas A; Frías-Iniesta J; Bethe U; Heringer S; Tischmann L; Zarrouk M; Cüppers A; König F; Posch M; Cornely OA
    Trials; 2022 Oct; 23(1):865. PubMed ID: 36209129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.